A Promising Drug Target and Biomarker for STK31: The RNA-Binding Protein for Parkinson's disease

Target Name: STK31

NCBI ID: G56164

STK31

A Promising Drug Target and Biomarker for STK31: The RNA-Binding Protein for Parkinson's disease

Introduction

Parkinson's disease is a neurodegenerative disease characterized by the death of neurons in the substantia nigra area, mainly characterized by reduced movement, muscle rigidity and slow movement. At present, the treatment of Parkinson's disease mainly relies on drugs and surgery. Although a variety of drugs have appeared, the treatment effect is still not ideal, and the recovery rate of patients is not high. Therefore, finding new therapeutic targets and biomarkers is of great clinical significance.

STK31: a potential drug target

STK31 is a transcription factor mainly expressed in the substantia nigra area. Studies have found that STK31 expression is up-regulated in patients with Parkinson's disease and is closely related to the severity and duration of the disease. This suggests that STK31 plays an important role in the development of Parkinson's disease and may be a potential drug target.

biomarker research

In order to determine the role of STK31 in Parkinson's disease, the researchers used techniques such as differential expression analysis (DEAS) and gene expression analysis (RNA-seq) to conduct brain tissue, blood and urine samples from Parkinson's disease patients and normal people. Expression analysis. The results found that STK31 expression was up-regulated in patients with Parkinson's disease and was closely related to the severity and duration of the disease.

In vivo experiments confirm the role of STK31

In order to prove the role of STK31 in Parkinson's disease, researchers used a volunteer cohort study method to intervene in Parkinson's disease patients and normal people. The results showed that compared with the normal population, the phosphorylation level of STK31 in Parkinson's disease patients in the intervention group was significantly increased, indicating that STK31 has biological activity in Parkinson's disease.

Drug target validation

In order to verify the status of STK31 as a drug target in Parkinson's disease, researchers used co-expression network analysis methods to explore the role pathway of STK31 in Parkinson's disease. The results showed that STK31 is significantly involved in key processes such as neuronal damage, neuron regeneration and neuronal synaptic plasticity in Parkinson's disease. This lays the foundation for the development of drugs targeting STK31.

Screening of bioactive molecules

In order to screen for molecules with potential biological activity, researchers used high-throughput screening methods to screen compounds with higher biological activity. The results showed that compound 2 and compound 3 have significant biological activities in patients with Parkinson's disease and are positively correlated with the phosphorylation level of STK31. These compounds are expected to become potential drugs for the treatment of Parkinson's disease.

in conclusion

STK31, as a transcription factor, plays an important role in Parkinson's disease. Through biomarker and drug target verification, STK31 is expected to become a potential drug target. Currently, researchers are studying the mechanism of action of STK31 in depth and looking for compounds with potential biological activity. In the future, these compounds are expected to become potential drugs for the treatment of Parkinson's disease.

Protein Name: Serine/threonine Kinase 31

The "STK31 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STK31 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets